On Invalid Date, Johnson & Johnson (NYSE: JNJ) reported Q4 2023 earnings per share (EPS) of $1.61, up 20.15% year over year. Total Johnson & Johnson earnings for the quarter were $4.05 billion. In the same quarter last year, Johnson & Johnson's earnings per share (EPS) was $1.34.
As of Q2 2024, Johnson & Johnson's earnings has grown 103.22% year over year. This is 103.08 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of 0.14%. Johnson & Johnson's earnings in the past year totalled $35.15 billion.
What was JNJ's revenue last quarter?
On Invalid Date, Johnson & Johnson (NYSE: JNJ) reported Q4 2023 revenue of $13.53 billion up 7.84% year over year. In the same quarter last year, Johnson & Johnson's revenue was $12.55 billion.
What was JNJ's revenue growth in the past year?
As of Q2 2024, Johnson & Johnson's revenue has grown 6.46% year over year. This is 1.84 percentage points higher than the US Drug Manufacturers - General industry revenue growth rate of 4.62%. Johnson & Johnson's revenue in the past year totalled $85.16 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.